Previous 10 | Next 10 |
The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of a subcutaneous formulation of Johnson & Johnson's ( JNJ -0.6% ) multiple myeloma med Darzalex (daratumumab). More news on: Johnson & Johnson, Genmab A/S, Healthcare stocks new...
Intro & pipeline Agenus ( AGEN ) is an immuno-oncology ((IO)) company with a deep and diversified pipeline, a technology for novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing. Agenus believes that the...
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing Canada NewsWire NEW YORK, March 26, 2020 NEW YORK , March 26, 2020 /CNW/ - Deutsche Bank today announced that the presentations from the March 18 th and 19...
NEW YORK , March 26, 2020 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the March 18 th and 19 th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companie...
Today, we will see why Genmab (GMAB) is an attractive biotech pick in March 2020. Company overview Genmab is a dual-listed biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company was founded in 19...
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020 Canada NewsWire NEW YORK, March 10, 2020 NEW YORK , March 10, 2020 /CNW/ - Deutsche Bank today announced the lineup for its Deposi...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
Drug regulators in the U.S. and EU have accepted Novartis ' (NYSE: NVS) applications to expand their approvals of ofatumumab to include patients with multiple sclerosis. The Food and Drug Administration is giving the marketing application a priority review, so a decision should come by this J...
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q4 2019 Earnings Call Feb 19, 2020 , 12:00 p.m. ET Operator Continue reading
Genmab A/S (GNMSF) Q4 2019 Earnings Conference Call February 19, 2020 12:00 PM ET Company Participants Jan van de Winkel - Chief Executive Officer David Eatwell - Chief Financial Officer Anthony Pagano - American Senior Vice President, Finance & Corporate Development Confe...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...